Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00115427

Enrollment

Unknown

Registered

2005-06-23

Start date

2003-03-31

Completion date

Unknown

Last updated

2008-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Parkinson's Disease

Keywords

Bilateral, Idiopathic Parkinson's Disease

Brief summary

This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.

Interventions

DRUGLiatermin (r-metHuGDNF)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

- Diagnosis of bilateral, idiopathic Parkinson's disease

Design outcomes

Primary

Measure	Time frame
United Parkinson's Disease Rating Scale	—

Secondary

Measure	Time frame
Timed Motor Tests	—
Dyskinesia ratings	—
Diary ratings	—
Patient reported outcomes measures	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026